Table 2.

Results of individual patient data analysis

SJS	Infliximab	Etanercept	Adalimumab	p value
Number of cases (n)		17
Age (years)		39.42 ± 18.76
Sex (male/female/missing) (n)		6/6/5
BSA (%)		8.40 ± 2.07 (7/10)
SCORTEN (n)
0–1		8
2		3
3		1
4		3
≥ 5		2
Undefined		0
Days after symptom onset therapy given (days)		11.50 ± 3.54 (2/17)
Time of reepithelialization (days)		5.67 ± 2.31 (3/17)
Hospitalization time (days)		11.36 ± 2.87 (11/17)
Mortality rate (%)		0% (0/17)
Number of patients reported sequelae (%)		0% (0/17)

SJS/TEN overlap	Infliximab	Etanercept	Adalimumab	p value
Number of cases (n)	3	9
Age (years)	70.33 ± 4.73	38.57 ± 27.47
Sex (male/female/missing) (n)	2/1/0	1/6/2
BSA (%)	20.0 ± 5.0	19.75 ± 2.76
SCORTEN (n)
0–1		2
2		2
3	1	1
4	1	1
≥ 5
Undefined	1	3
Days after symptom onset therapy given (days)	3.67 ± 2.52 (3/3)	4.60 ± 2.88 (5/9)
Time of reepithelialization (days)	NA	11.83 ± 9.58 (6/9)
Hospitalization time (days)	20.50 ± 2.12 (2/3)	14.4 ± 7.06 (5/9)
Mortality rate (%)	33.3% (1/3)	0% (0/9)
Number of patient-reported sequelae (%)	0% (0/3)	0% (0/9)

TEN	Infliximab	Etanercept	Adalimumab	p value
Number of cases (n)	28	64	4
Age (years)	40.71 ± 25.68	48.61 ± 25.70	38.75 ± 19.79	0.348
Sex (male/female/missing) (n)	12/16/0	26/33/5	0/0/4	0.915
BSA (%)	58.33 ± 25.95	58.25 ± 21.04	66.25 ± 24.28 (4/4)	0.805
SCORTEN (n)				0.405
0–1	0	5	1
2	4	8	1
3	2	16	1
4	3	11	1
≥ 5	1	11	0
Undefined	18	13	0
Days after symptom onset therapy given (days)	5.67 ± 3.45 (24/28)	4.60 ± 7.01 (53/64)	1.50 ± 3.00 (4/4)	0.424
Time of reepithelialization (days)	12.5 ± 13.98 (20/28)	10.47 ± 4.98 (45/64)	17.24 ± 12.69 (4/4)	0.104
Hospitalization time (days)	22.58 ± 13.87 (12/28)	21.24 ± 11.96 (21/64)	22.75 ± 8.81 (4/4)	0.944
Mortality rate (%)	14.3% (4/28)	12.5% (8/64)	0% (0/4)	0.673
Number of patient-reported sequelae (%)	39.3% (11/28)	6.4% (10/64)	0% (0/4)	0.022

NA not applicable, SJS Stevens–Johnson syndrome, TEN toxic epidermal necrolysis

p value: etanercept versus infliximab